Trevi Therapeutics Announces Notice of Allowance for U.S. Pa

NEW HAVEN, Conn., March 8, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults w...

Related Keywords

United States , Rosalia Scampoli , Katie Mcmanus , Trevi Haduvio , Exchange Commission , Trademark Office , Linkedin , Prnewswire Trevi Therapeutics Inc , Nasdaq , Trevi Therapeutics Inc , United States Patent , Orange Book Listable , Jennifer Good , Chronic Cough , Idiopathic Pulmonary , Trevi Therapeutics , Private Securities Litigation Reform Act ,